¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"complement system"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
¿µ¹® musculoskeletal System ÇÑ±Û ±Ù°ñ°Ý°è
¼³¸í   
  ±ÙÀ°°ú À̵頱ÙÀ°ÀÌ ºÙ¾î¼­ °°À̠Ȱµ¿À» ¼öÇàÇϴ °ñ°Ý(»À¸¦ ÅëÅо»ÇÔ)À» ÇÔ²² ºÎ¸£´Â ¸». µû¶ó¼­ ¿©±âÀÇ ±ÙÀ°Àº ¸ðµÎ °¡·Î¹«´Ì±Ù¿¡ ¼ÓÇϸç, ¼öÀÇÀûÀ¸·Î ¿òÁ÷ÀÏ ¼ö ÀÖ´Ù.
¿µ¹® muscular system ÇÑ±Û ±ÙÀ°°èÅë
¼³¸í   
  ±ÙÀ°¿¡ ÀÇÇØ ÀÌ·ç¾îÁø ÇϳªÀÇ °èÅëÀ» ÀÓÀÇÀûÀ¸·Î ³ª´©¾î ºÎ¸¥ ¸».
¿µ¹® male reproductive system ÇÑ±Û ³²¼º»ý½Ä±â°è
¼³¸í   
  ³²¼ºÀÇ »ý½Ä±â´Â ¿©·¯ ±â°üÀ¸·Î ±¸¼ºµÇ¾î ÀÖ´Ù. °íȯ, ºÎ°íȯ, Á¤°ü, Á¤³¶, Àü¸³»ù, ¿ÜºÎ¼º±â(À½°æ) µîÀ¸·Î ±¸¼ºµÇ´Âµ¥, ½ÇÁ¦ÀûÀ¸·Î Á¤ÀÚ¸¦ »ý¼ºÇϴ °÷Àº ´Ü ÇÑ °÷ °íȯ»ÓÀ̸ç, ³ª¸ÓÁö ±â°üÀº À̸¦ µ½´Â ±â´ÉÀ» ¼öÇàÇϰí ÀÖ´Ù. Á¤Àڴ °íȯÀÇ Á¤¼¼°üÀ̶õ °÷¿¡¼­ ¸¸µé¾îÁø µÚ¿¡ ¹ÛÀ¸·Î ³ª¿Í ±ä ¿©Á¤À» ½ÃÀÛÇϰԠµÈ´Ù. ±× µÚ ºÎ°íȯÀ» Áö³ª Á» ´õ ¼º¼÷ÇØ Áø µÚ¿¡ Á¤°ü¿¡¼­ Á¤³¶ÀÇ ºÐºñ¹°°ú ¸¸³ª°í ´Ù½Ã ¿äµµ·Î ³ª°¡°Ô µÈ´Ù. À̶§ ¿äµµ µÚÂÊ¿¡ À§Ä¡Çϴ Àü¸³»ùÀÇ ºÐºñ¹°ÀÌ ÇÕÃÄÁö°Ô µÇ°í ÀÌ Á¤¾×Àº ¿ÜºÎ¼º±â¸¦ °ÅÃļ­ ¹ÛÀ¸·Î ³ª°¡°Ô µÈ´Ù.
  
  ³²¼º»ý½Ä±â°è
¿µ¹® lymphatic system ÇÑ±Û ¸²ÇÁ°è
¼³¸í   
  ´ë°³ ¸Æ°ü°è¶ó°í Çϸé, Ç÷°ü°è¿Í ¸²ÇÁ°ü°è¸¦ ÇÕÃļ­ ¸»ÇÑ´Ù. ÀÌÁß¿¡ ¸²ÇÁ¿¡ ÀÇÇØ ÀÌ·ç¾îÁö´Â ÇϳªÀÇ °èÅëÀÌ´Ù.
¿µ¹® immune system ÇÑ±Û ¸é¿ªÃ¼°è
¼³¸í   
  ¼¼Æ÷¼ººÐ ¹× ºÐÀÚ¼ººÐÀÇ º¹ÇÕü°è·Î¼­, ÀÌÀÇ ÀÏÂ÷±â´ÉÀº ÀÚ±â(self)¸¦ ºñÀÚ±â(not self)·ÎºÎÅÍ ±¸º°ÇÏ°í ¿ÜºÎ»ý¹° ¶Ç´Â ¹°Áú¿¡ ´ëÇØ ¹æ¾îÇϴ °ÍÀÌ´Ù. ÀÏÂ÷ÀûÀΠ¼¼Æ÷¼ººÐÀº ¸²ÇÁ±¸¿Í Å«Æ÷½Ä¼¼Æ÷À̸ç ÀÏÂ÷ÀûÀΠºÐÀÚ¼ººÐÀº Ç×ü¿Í ¸²Æ÷Ä«ÀÎÀÌ´Ù.
  
  
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • complement-fixing antibody
    º¸Ã¼°áÇÕÇ×ü, µµ¿òü°áÇÕÇ×ü
  • complement-induced
    º¸Ã¼À¯µµ-
  • complement-mediated
    º¸Ã¼¸Å°³-
  • complement-mediated cytotoxicity
    º¸Ã¼¸Å°³¼¼Æ÷µ¶¼º
  • dominant complement
    ¿ì¼ºº¸Ã¼
  • Apgar scoring system
    ¾ÆÇÁ°¡Á¡¼öÆò°¡¹ý
  • array system
    ¹è¿­ÀåÄ¡, ¹è¿­Ã¼°è
  • auditory system
    û°¢°èÅë, û°¢°è
  • autonomic nervous system
    ÀÚÀ²½Å°æ°èÅë, ÀÚÀ²½Å°æ°è
  • ABO blood group system
    ABOÇ÷¾×Çüü°è
  • air medical transport system
    Ç×°øÀÇ·á¼ö¼Ûü°è
  • alimentary system
    ¼ÒÈ­°èÅë, ¼ÒÈ­°è
  • Bethesda system
    º£µ¥½º´ÙºÐ·ù(¹ý)
  • biliary system
    ¾µ°³°èÅë, ´ãµµ°è
  • blood group system
    Ç÷¾×Çüü°è
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • reproductive system
    »ý½Ä°èÅë
  • respiratory system
    È£Èí°èÅë
  • reticuloendothelial system
    ±×¹°³»ÇǰèÅë, ¼¼¸Á³»ÇǰèÅë
  • stereotactic system
    Á¤À§°íÁ¤±â
  • urinary system
    ºñ´¢°èÅë
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • complement typing
    º¸Ã¼Çüº°°Ë»ç
  • complement deficient state
    µµ¿òü°áÇÌ»óÅÂ, º¸Ã¼°áÇÌ»óÅÂ
  • complement fixation reaction
    º¸Ã¼°áÇÕ¹ÝÀÀ, µµ¿òü°áÇÕ¹ÝÀÀ
  • complement fixation test
    µµ¿òü°áÇÕ½ÃÇè, º¸Ã¼°áÇÕ½ÃÇè
  • complement fixation unit
    º¸Ã¼°áÇÕ´ÜÀ§
  • complement fixation inhibition test
    º¸Ã¼°áÇÕ¾ïÁ¦½ÃÇè
  • complement mediated lysis
    º¸Ã¼¸Å°³¿ëÇØ, µµ¿òü¸Å°³¿ëÇØ
  • complement-dependent cytotoxicity
    µµ¿òüÀÇÁ¸¼¼Æ÷µ¶¼º
  • complement-mediated cytotoxicity
    µµ¿òü°ü·Ã¼¼Æ÷µ¶¼º
  • dominant complement
    ¿ì¼ºµµ¿òü
  • ABO blood group system
    ¿¡À̺ñ¿ÀÇ÷¾×Çü±º
  • aerospace life support system
    ¿ìÁÖ»ý¸íÀ¯Áö°èÅë
  • affectional system
    Á¤µ¿Ã¼°è, °¨Á¤Ã¼°è
  • alimentary system
    ¼ÒÈ­°èÅë
  • anaerobic culture system
    ¹«»ê¼Ò¹è¾ç±â
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Bactec system
    ¹ÚÅØ°èÅë
  • Control system
    Á¶Àý°è(ðàï½Í§)
  • DNA repair system
    DNA ·¹Çø®ÄÉÀ̽º ½Ã½ºÅÛ.
  • DNA repair system
    DNA º¸¼ö±â±¸.
  • DOS (disk operating system)
    µð½ºÅ© ¿î¿µ üÁ¦
  • Diego blood group system
    µð¿¡°í Ç÷¾×Çü°è
  • Duffy system
    ´õÇǰè.
  • Female reproductive system
    ¿©¼º(Ò³àõ)»ý½Ä±â°ü(ßæãÖÐïί)
  • Fibrinolytic system
    ¼¶À¯¼Ò¿ëÇØ°è(¡­Ìõ)
  • Fisher-Race system
    Çǽ¬-·¹À̽º ½Ã½ºÅÛ
  • Gastrointestinal system
    À§Àå°ü°è(êÖíóηͧ)
  • General anesthesia, reticular activating system and.
    Àü½Å¸¶Ãë(îïãóئö­), ¸Á»óüȰ¼ºÈ­°è(ØÑßÒô÷üÀàõûùͧ)
  • Glycogen-lactic acid system
    ±Û¸®ÄÚ°Õ-¶ôÆ®»ê°è
  • Haversian system
    »À ´ÜÀ§<°ñ¿ø>, ÇϹö½º °èÅë(¡­Í§÷Ö).
  • Haversian system
    »À´ÜÀ§<°ñ¿ø>, ÇϹö½º°è Åë(¡­Í§÷Ö).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • complement consumption test
    º¸Ã¼¼Òºñ½ÃÇè(¡­á¼Þ¨ãËúÐ).
  • complement consumption test
    º¸Ã¼¼Òºñ½ÃÇè(¡­á¼Þ¨ãËúÐ).
  • complement consumption test
    º¸Ã¼¼Òºñ½ÃÇè(¡­á¼Þ¨ãËúÐ).
  • complement deficiency
    º¸Ã¼°áÇÌ
  • complement deficient state
    º¸Ã¼°áÇÌ»óÅÂ
  • complement dependent cytotoxicity
    º¸Ã¼ÀÇÁ¸¼º ¼¼Æ÷µ¶¼º
  • complement fixation =CF
    º¸Ã¼°íÁ¤(¡­Í³ïÒ).
  • complement fixation =CF
    º¸Ã¼°áÇÕ(¡­Ì¿ùê).
  • complement fixation inhibition test
    º¸Ã¼°íÁ¤ÀúÇØ½ÃÇè(ÜÍô÷ͳïÒîÁúªãËúÐ).
  • complement fixation inhibition test
    º¸Ã¼°áÇÕÀúÇØ½ÃÇè(ÜÍô÷Ì¿ùêîÁúªãËúÐ).
  • complement fixation reaction
    º¸Ã¼°áÇÕ¹ÝÀÀ(¡­Úãëë).
  • complement fixation test
    º¸Ã¼°áÇÕ½ÃÇè
  • complement fixation test =CFT
    º¸Ã¼°íÁ¤½ÃÇè(¡­ãËúÐ).
  • complement fixation test =CFT
    º¸Ã¼°áÇÕ½ÃÇè(¡­ãËúÐ).
  • complement fixation test, indirect
    °£Á¢º¸Ã¼°áÇÕ½ÃÇè
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cell-free amino acid incorporating system
    ¹«¼¼Æ÷(Ùíá¬øà) ¾Æ¹Ì³ë»ê ÆíÀÔ(øºìý)¾¾½ºÅÛ
  • cell-free system
    ¹«¼¼Æ÷(Ùíá¬øà)½Ã½ºÅÛ
  • charge relay system
    ÀüÇÏ(ï³ùÃ) ¸±·¹ÀÌ ½Ã½ºÅÛ
  • charge transfer relay system
    ÀüÇÏÀ̵¿(ï³ùÃì¹ÔÑ) ¸±·¹ÀÌ ¾¾½ºÅÛ
  • closed circuit system
    Æó¼âȸ·Î(øÍáðüÞÖØ) ½Ã½ºÅÛ
  • closed system
    ´ÝÈù ½Ã½ºÅÛ
  • cyclophorase system
    »çÀÌŬ·ÎÆ÷·¹À̽º ½Ã½ºÅÛ
  • digestive system
    ¼ÒÈ­(á¼ûù)½Ã½ºÅÛ
  • DNA replicase system
    DNA ·¹Çø®ÄÉÀ̽º ½Ã½ºÅÛ (ÔÒ) replisome
  • ecological system
    »ýÅÂÇÐÀû(ßæ÷¾ùÊîÜ) ½Ã½ºÅÛ
  • electron transfer system
    ÀüÀÚÀü´Þ(ï³í­îîÓ¹) ½Ã½ºÅÛ
  • electron transport system
    ÀüÀÚ¼ö¼Û(ï³í­âÃáê) ½Ã½ºÅÛ
  • endocrine system
    ³»ºÐºñ¼±(Ò®ÝÂù²àÊ) ½Ã½ºÅÛ
  • endomembrane system
    ³»¸·(Үد) ½Ã½ºÅÛ
  • energy-regenerating system
    ¿¡³ÊÁö Àç»ý(î¢ßæ) ½Ã½ºÅÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • OS [=operating system]
    ¿î¿µÃ¼Á¦
  • PACS [=picture archiving and communicating system]
    ÆÑ½º, ¿µ»óÀúÀå ¹× Àü¼Ûü°è
  • portal system
    ¹®¸Æ°è
  • radiologic information system(RIS)
    ¹æ»ç¼±°ú Á¤º¸È­Ã¼°è
  • real time system
    ½Ç½Ã°£Ã¼°è
  • reproductive system
    »ý½Ä±â°èÅë
  • reticuloendothelial system
    ¼¼¸Á³»Çǰè, ¸Á³»°è
  • urinary system
    ºñ´¢±â°è
  • vegetative nervous system
    ÀÚÀ²½Å°æ°è
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MEOS Microsomal Ethanol Oxidizing System
  = MFOS; Mixed Function Oxidase System
TNM staging System standard Tumor, NOde & Metastasis staging system
ARMS adverse reaction monitoring system; amplification refractory mutation system
CSD carotid sinus denervation; cat scratch disease; combined system disease; conditionally streptomycin ...
FCS faciocutaneoskeletal syndrome; fecal containment system; feedback control system; fetal calf serum; ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CCP Complement Control Protein
CF Complement Fixation
CFT Complement Fixation
CFR Complement Fixation Reaction
CF Complement Fixation Test
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • affectional system
    Á¤µ¿ ü°è
  • afferent system
    ±¸½É ½Å°æ°è
  • alloy system
    Çձݰè
  • analgesia system
    ÁøÅë°è
    ÁßÃß ½Å°æ°è°¡ °¡Áø µ¿ÅëÀ» ÅëÁ¦ÇÏ´Â ÀÏ·ÃÀÇ ½Å°æ Á¶Á÷. ÁÖ·Î ½Å°æ ¼¼Æ÷¿¡¼­ o
  • aqueous system
    ¼ö¼º°è
  • ArF system emission spectra
    ArF°è ¹æÃâ ½ºÆåÆ®·³
  • ascending projection system
    »óÇà Åõ»ç°è
  • autologous blood recovery system
    ÀÚ°¡ Ç÷¾× ȸº¹ ÀåÄ¡
  • autonomic nervous system
    ÀÚÀ² ½Å°æ°è, ÀÚÀ² ½Å°æ°èÅë
    ºÒ¼öÀǼºÀ¸·Î »ýü ±â´ÉÀ» Á¶Àý. ½Åü Àü¹Ý¿¡ ÀÖ´Â ÆòȰ±Ù°ú ¼±Á¶Á÷¿¡ °ü¿©ÇÏ´Â ¸»ÃʽŰæ°èÀÇ ÀϺκÐÀÌ´Ù. À̰ÍÀº ¿îµ¿
  • autonomic nervous system arousal
    ÀÚÀ² ½Å°æ°è °¢¼º
  • bicarbonate buffer system
    Áßź»ê¿° ¿ÏÃæ°è
  • biliary system
    ´ã³¶°è
  • biomedical classification system
    »ýÀÇÇÐÀû ºÐ·ù ü°è
  • breathing system
    È£Èí ÀåÄ¡
  • buffer system
    ¿ÏÃæ°è
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
complement 3b <chemical> The larger fragment formed when c3 convertase splits c3 into c3a and c3b. In both the classical and alternate pathway, c3b participates in immune adherence and enhances phagocytosis. It also forms a cellular intermediate which continues the complement process. In the alternate pathways, c3b initiates a positive feedback activation of c3pase.
Chemical name: Complement C3b
(12 Dec 1998)
complement 3b inactivators Compounds which inhibit, antagonise, or inactivate complement 3b. A well-known inhibitor is a beta-globulin which cleaves c3b into inactive fragments c3c and c3d. C3bina plays a key role in the regulation of the complement system by blocking the cytolytic sequence and preventing recruitment of the properdin amplification loop.
(12 Dec 1998)
complement 3c <chemical> An inactivated form of complement 3b (c3b). Complement 3b is inactivated with the help of two regulatory factors, complement factor h and complement factor I. Complement factor h (c3b inactivator accelerator) makes c3b susceptible to the serine protease, complement factor I (formerly called kaf, c3binf, or enzyme 3b inactivator), to form ic3b. Then complement factor I and a trypsin-like proteolytic enzyme further cleave ic3b into c3c and c3dg.
Chemical name: Complement C3c
(12 Dec 1998)
complement 3 convertase <enzyme> The enzyme which in both the classical and alternate complement pathways cleaves complement 3 into anaphylatoxin (c3a) and c3b.
Registry number: EC 3.4.21.43
(12 Dec 1998)
complement 3d <chemical> An inactivated fragment of complement 3b (c3b). Factor h makes c3b susceptible to factor I (formerly called kaf, c3binf, or enzyme 3b inactivator) to form ic3b. Then factor I and a trypsin-like proteolytic enzyme further cleave ic3b into c3c and c3dg. Serum proteases degrade c3dg into complement 3d (c3d) and c3g.
Chemical name: Complement C3d
(12 Dec 1998)
complement 3 nephritic factor A magnesium-dependent IgG autoantibody found in serum of patients with chronic mesangioproliferative hypocomplementemic glomerulonephritis. It causes inactivation of c3 in the alternate pathway by cleaving c3 into two inactive fragments, c3c and c3d, instead of the normal c3b.
(12 Dec 1998)
complement 4 The second component to react in the complement sequence. It is a beta-globulin with a sedimentation coefficient of 18.7, a molecular weight of 240,000 and a serum concentration of 430 micrograms/ml. It is activated by complement 1 and serves as a receptor for c2.
(12 Dec 1998)
complement 4a <chemical> Smaller fragment formed when c1s splits c4 into c4a and c4b. As an anaphylatoxin, c4a causes symptoms of immediate hypersensitivity but it has weaker activity than c3a or c5a.
Chemical name: Complement C4a
(12 Dec 1998)
complement 4b <chemical> Larger fragment formed when c1s splits c4 into c4a and c4b. C4b combines with c2b to form the activated c4b2b complex which is often called the classical pathway c3 convertase.
Chemical name: Complement C4b
(12 Dec 1998)
complement 5 The fifth component in the complement reaction sequence, probably exists in a complex with c6 and c7. It is a beta-globulin with a sedimentation coefficient of 10, serum concentration of 75 micrograms/ml and molecular weight of 180,000. It is activated by c423 and releases fragments with anaphylatoxic, chemotactic, and histamine-releasing actions and affecting smooth muscle.
(12 Dec 1998)
complement 5a <chemical> Smaller fragment formed when c5 convertase splits c5 into c5a and c5b. C5a is a 74-amino acid peptide that includes a carboxy-terminal arginine crucial for its spasmogenic activity and a carbohydrate moiety. C5a is the most potent anaphylatoxin mediating immediate hypersensitivity.
Chemical name: Complement C5a
(12 Dec 1998)
complement 5a, des-arginine Complement 5a with the carboxy-terminal arginine removed. The arginine is rapidly cleaved from the c5a fragment during complement activation by carboxypeptidase b present in normal human serum. C5a des-arg shows complete loss of spasmogenic activity though it retains some chemotactic ability.
(12 Dec 1998)
complement 6 The sixth component in the complement reaction sequence. It is a beta-globulin with a sedimentation coefficient of 8.7 and a molecular weight of 120,000 at 60 micrograms/ml in serum. It may exist in a complex with c5 and c7 and is activated by the binding of c5.
(12 Dec 1998)
complement 7 The seventh component in the complement reaction sequence. It is a beta-globulin probably in a complex with c5 and c6 and is activated by c5. The attachment of c7 renders the cell susceptible to lysis.
(12 Dec 1998)
complement 8 The next to the last essential component for cell lysis in the complement reaction sequence. It is a gamma-globulin with a molecular weight of 150,000 and a sedimentation coefficient of 8. It is present in trace amounts in serum and can be inhibited, like complement 1, by cation chelators.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Information Network System
    °íµµ Á¤º¸ Åë½Å ½Ã½ºÅÛ
  • Montessori method(system)
    (ÀÌÅ»¸®¾ÆÀÇ ¿©¼º ±³À°°¡ À̸§¿¡¼­) ¸óÅ×¼Ò¸®½Ä ±³À°¹ý(¾Æµ¿ÀÇ ÀÚÁÖ¼ºÀÇ ½ÅÀåÀ» Áß½ÃÇÑ ±³À°¹ý) m`
  • PA system
    =PUBLICADDRESS SYSTEM
  • Ptolemaic system
    õµ¿¼³
  • ascent propulsion system
    ¿ìÁÖ Á¤°ÅÀå ±Íȯ¿ë ·ÎÄÏ ¿£Áø
  • barter system
    ¹ÙÅÍÁ¦
  • call connect system
    ÀüÈ­ Á¢¼Ó±â(¿Ü¼±.³»¼± ÀüÈ­¿ÍÀÇ)
  • case system
    ÆÇ·Ê Áß½ÉÀÇ ±³À°¹ý 1
  • centerofmass system
    Á߽ɰè(°èÀÇ Áß½ÉÀÇ ¿îµ¿·®ÀÌ ¿µÀÌ µÇµµ·Ï ÃëÇÑ ÁÂÇ¥°è)
  • central alarm system
    Áß¾Ó °æº¸ ÀåÄ¡(ÀÚµ¿ÀûÀ¸·Î °æÂû.°æºñ ȸ»ç µî¿¡ Å뺸µÇ´Â)
  • central nervous system
    ÁßÃß ½Å°æ°è
  • chit system
    ÀüÇ¥ ÁöºÒÁ¦
  • circulatory system
    ¼øÈ¯°è(Ç÷¾×À̳ª ¸²ÇÁ¾×ÀÌ È帣°Ô ÇÏ´Â)
  • closed ecological system
    »ýÅÂÇÐÀû Æó¼â°è
  • cold type system
    Äݵå ŸÀÌÇÁ ½Ã½ºÅÛ(³³È°ÀÚ³ª ¿­À» »ç¿ëÇÏÁö ¾Ê°í Çʸ§À» ÁÖü·ÎÇÑ »ç½ÄÈ­¿¡ ÀÇÇÑ Àμ⠰øÁ¤
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á